title: A clinical review on extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer using nonrobotic linear accelerators.
abstract: Seven phase I-II studies fell within the inclusion criteria. Details on the radiotherapy technique, patient selection, fractionation scheme, exclusion criteria, treatment toxicity, quality-of-life, and tumor control were collected. The studies provide encouraging results of acute and late toxicity, with rare grade 3 events, that seem comparable to robotic SBRT. The biochemical disease-free survival rates look promising, but most patients belong to the low-risk group. The trials are limited by a short follow-up, small number of patients, and different approaches in prescribing dose and defining the acceptable dose heterogeneities. Currently, nonrobotic SBRT regimens should be used in the context of clinical trials.
authors.affiliation: Department of Radiation Oncology, Salamanca University Hospital, Salamanca, Spain.
authors.forename: Victor A
authors.initials: VA
authors.lastname: Macias
authors.forename: Luis A
authors.initials: LA
authors.lastname: Perez-Romasanta
mesh_terms: D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D006801:Humans; D008297:Male; D010315:Particle Accelerators; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011788:Quality of Life; D016634:Radiosurgery / Q000009:adverse effects* / Q000379:methods; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000528:radiation effects